Cardiology

Examining individual pregnancy outcomes rather than defining women by the presence or absence of complications more reliably predicts later CVD death.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia and the FDA approval of Furoscix ReadyFlow.

July saw some of the biggest FDA approvals so far in 2026 – catch up on what you might have missed!

All cardiovascular disease risks decreased proportionately across all quintiles of diet consistency, according to recent data.

John Giacona, PhD, PA-C, discusses building a comprehensive multidisciplinary care team for interstitial lung disease and how APPs should engage with clinical evidence.

The IL-6 inhibitor missed its primary MACE endpoint in ASCVD, CKD, and inflammation despite expected biological effect on target engagement.

The ACC's new decision pathway incorporates SGLT2 inhibitor finerenone and data on incretin therapy into HFpEF diagnosis and management guidance.

John Giacona, PhD, PA-C, discusses the cardiology perspective on screening for and managing pulmonary hypertension in interstitial lung disease.

CaRi-Heart measures coronary inflammation from routine CT angiography and generates a personalized 10-year cardiovascular mortality risk score.

Phoenix PAH specialists discuss RHC-guided monitoring, sotatercept shunting and erythrocytosis signals, meth-PAH management, and prostacyclin transition strategies.

The FDA has officially granted Fast Track designation to HTX-001 for the treatment of non-obstructive hypertrophic cardiomyopathy.

The Voluntary Sodium Reduction Goals, issued in October 2021, resulted in no significant reduction in sodium content among packaged foods.

Abbas Zaidi, MD, discusses his recent study providing 5 pain points and 5 suggested improvements for the pediatric hypertension treatment flow.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia, the FDA approval of Furoscix ReadyFlow, and more.

The approval makes MannKind Corporation’s furosemide injection the first and only autoinjector delivering SC furosemide with IV-equivalent exposure.

Ann Marie Navar, MD, PhD, highlights enlicitide’s FDA approval for hypercholesterolemia and its potential to fundamentally change therapy.

Plozasiran cut triglycerides up to 81% and reduced acute pancreatitis events in phase 3 SHASTA-3, SHASTA-4 trials for severe hypertriglyceridemia.

According to a recent study, nearly 32.2% of US adults are well above their LDL-C targets to avoid atherosclerotic cardiovascular disease.

After broadening eligibility criteria across several disease states and a wider age range, the new guidelines have made an estimated 87.5 million adults eligible for statins.

Stay updated with the latest healthcare breakthroughs, including FDA approvals, phase 3 data, and open-label extension results.

Ron Blankstein, MD, discusses a secondary analysis of Heartflow’s DECIDE registry, indicating undetected cardiovascular risk in patients previously labeled safe.

Sanjay Rajagopalan, MD, discusses the need for more patient-specific air pollution warnings to optimize accessibility for all individuals.

Ann Marie Navar, MD, PhD, discusses the groundbreaking approval of the first oral PCSK9 inhibitor and what it means for patients managing their LDL-C levels.

A recent analysis of data from the Global Burden of Disease Study has indicated a relationship between risk of death from ACHD and socioeconomic factors.

A multidisciplinary clinical forum discussed diagnosis, referral thresholds, and the evolving APOC3-targeted treatment landscape for FCS.